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The p53 family member p63 has been shown to be critical for growth, proliferation and chemosensitivity. Here we demonstrate
that the c-Abl tyrosine kinase phosphorylates the widely expressed DNp63a isoform and identify multiple sites by mass
spectrometry in vitro and in vivo. Phopshorylation by c-Abl results in greater protein stability of both ectopically expressed and
endogenous DNp63a. c-Abl phosphorylation of DNp63a induces its binding to Yes-associated protein (YAP) and silencing of
YAP by siRNA reduces the c-Abl-induced increase of DNp63a levels. We further show that cisplatin induces c-Abl
phosphorylation of DNp63a and its binding to YAP. Overexpression of DNp63a, but not the c-Abl phosphosites mutant, protects
cells from cisplatin treatment. Finally, we demonstrate the rescue of p63 siRNA-mediated loss of viability with p63siRNA
insensitive construct of DNp63a but not the phosphosites mutant. These results demonstrate that c-Abl phosphorylation of
DNp63a regulates its protein stability, by inducing binding of YAP, and is critical for cell viability.
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The p53 family of transcription factors consists of three
members, each transcribed from separate genes, p53, p63
and p73. p53 was the ﬁrst family member to be discovered,
and transgenic mice studies and mutational analyses in
human cancers have implicated p53 to be one of the most
important tumor suppressors.
1 Functionally, p53 responds to
a variety of stresses in the cell and acts to protect DNA from
damage. p73 and p63 were discovered later and both
preliminary transgenic studies and mutational analyses
yielded little evidence for a direct role for these two family
members in tumorigenesis.
2,3 Indeed, p73 and p63 were
shown to have a role in development, with p73 thought to be
pivotal for the formation of neural system and p63 necessary
for skin development.
4–6 However, recent studies have
determined that p73 is critical for the response to DNA
damage induced by chemotherapeutics and that p63 also has
avitalroleinprotectingthefemalegermlinefromradiationand
chromosomal damage.
7,8 Moreover, p63 and p73 have been
shown to cooperate with p53 in regulating both apoptosis and
tumorigenesis.
9,10
The p63 and p73 genes can each be transcribed from two
promoters, generating full-length transactivation domain
containing TA isoforms or N-terminal truncated DNi s o f o r m s ,
whichcontainashortuniquetransactivationdomaindepending
on promoter usage. Even greater complexity is generated by
the fact that these isoforms can undergo alternative
C-terminal splicing generating a total of 6 different p63
isoforms and at least 14 p73 isoforms.
11 The expression level
of each isoform differs in various tissues and stages of
development and the overall combined activity of the p53
family in any given scenario will be dependent on the ratio of
the isoforms present and their interaction.
11 This was clearly
demonstrated in a recent transgenic study in mice that
demonstrated that p73 can be a tumor suppressor in it is
own right, but only if the TA isoform is knocked out.
12
Though the three family members are structurally homo-
logous and can be activated by similar stresses to regulate a
comparable set of genes, they are differentially regulated by
upstream signaling. For example, p53 is phosphorylated by a
host of serine/threonine kinases, whereas p73 is phosphory-
lated by the tyrosine kinase c-Abl upon DNA damage.
13–16
They also bind to and are degraded by different E3 ubiquitin
ligases; MDM2 is well-characterized as one of the key
regulators of p53 but not p73, whereas ITCH has recently
been shown to control the stability of both p63 and p73 but
does not bind p53.
17–19
Another protein that binds p73 but not p53 is the Yes-
associated protein (YAP).
20 YAP binds p73 and promotes its
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been shown to be negatively regulated by Akt and stimulated
by DNA damage, in part, through c-Abl.
21–24 More recently,
YAP has been shown to also stabilize p73 by displacing ITCH
by competitive binding.
25,26
In this study, we demonstrate that the widely expressed
DNp63a isoform of p63 is directly phosphorylated by c-Abl
both in vitro and in vivo. Phosphorylation of DNp63a promotes
increased binding to YAP and results in its increased stability.
c-Abl activity can signal a wide spectrum of cellular processes
including apoptosis, proliferation and differentiation.
27
Though cisplatin induced c-Abl phosphorylation of TA p73
and YAP has previously been shownto be pro-apoptotic, here
we show that c-Abl-phosphorylated DNp63a in head and neck
cancer cells promotes greater proliferation and protection
from cisplatin-induced cell death.
Results
Identiﬁcation of in vitro and in vivo c-Abl
phosphorylation of DNp63a. We noted that the c-Abl
phosphorylation site identiﬁed in TAp73 is conserved in
both TA and DN isoforms of p63. To gain insight into the
possible role of c-Abl phosphorylation of p63, we focused on
the widely expressed DNp63a isoform. We ﬁrst assessed the
direct phosphorylation of DNp63a by carrying out in vitro
kinase assays employing recombinant proteins. As shown in
Figure 1a, tyrosine phosphorylation as well as a visible band
shift of p63 was detected in SDS-PAGE fractionation of c-Abl
but not control kinase assays, in an ATP-dependent manner.
Co-transfection in cells with either empty vector, full-length
c-Abl, an activating SH3 truncated mutant c-Abl or an
inactive SH2, SH3 truncation mutant c-Abl
28 reveals similar
c-Abl dependent, in vivo tyrosine phosphorylation of DNp63a
(Figure 1b). Mass spectrometric analysis of DNp63a from
in vitro kinase assays identiﬁed six putative, direct c-Abl-
dependent tyrosine phosphorylation sites (Supplementary
Figure S1a), whereas analysis of p63 immunoprecipitated
from cells co-transfected with active c-Abl yielded seven
tyrosine phosphorylation sites (Supplementary Figure S1b).
There were three phosphorylated residues detected that
overlapped from in vitro and in vivo analyses (Figure 1c).
These were selected for further analyses to focus on sites
that were most likely to be directly phosphorylated by c-Abl
as well as being physiologically relevant. One of these sites,
Y55, is the homologous site of c-Abl phosphorylation
identiﬁed on p73. The second site, Y137, is also conserved
in p73 but has not previously been reported to be
phosphorylated, whereas the third site, Y308, is only found
in p63 isoforms. The ﬁrst two sites are conserved in p63
isoforms from zebraﬁsh to human, whereas the third site is
conserved from frog to human (Figure 1c). Phospho-deﬁcient
tyrosine to phenylalanine point mutant constructs of each site
(Y55F, Y137F and Y308F), as well as a combined mutant
construct (YYYFFF) were generated. Co-transfection of
wild-type DNp63a and the mutants constructs with c-Abl
demonstrated that each of the three sites were
phosphorylated in vivo and that ablating all three is
necessary for abrogating c-Abl-dependent tyrosine
phosphorylation of p63 (Figure 1d). It is interesting to note
that mutation analysis also revealed that a commercial
antibody (p-p73Y99) to the c-Abl-phosphorylated tyrosine,
Y99, of TAp73 cross-reacts speciﬁcally to the conserved
tyrosine, Y55, on DNp63a.
Endogenous DNp63a stability is regulated by c-Abl
phosphorylation. We noted that in Figure 1b, co-
transfection of DNp63a with the more active DSH3 c-Abl
mutant in 293 cells increased its protein stability relative to
co-expression with the less active full-length c-Abl.
Furthermore, in Figure 1d we see that the phosphosite
mutants are markedly less stable than wild-type DNp63a,
with the triple mutant exhibiting least stability. To assess
whether c-Abl regulates endogenous DNp63a, we examined
head and neck cancer cells, in which the DNp63a isoform is
expressed at high levels and has been shown to be vital for
proliferation, differentiation, growth and protection from
p73-dependentapoptosis.
29–31Weectopicallyexpressedc-Abl
in the H357 head and neck cancer cell line and immuno-
precipitated endogenous DNp63a with an a isoform
selective p63 antibody. Western blot with phosphotyrosine
antibody from c-Abl, but not empty vector transfected
cells, demonstrate robust tyrosine phosphorylation of
DNp63a (Figure 2a). Similar to what was shown in 293
cells (Figure 1b), transfection of c-Abl increased expression
of endogenous DNp63a over transfection of empty vector in
the head and neck cancer cells (Figure 2b). This effect was
further enhanced by transfection with the hyperactive
DSH3 c-Abl construct (Figure 2b). In contrast, silencing
endogenous c-Abl with siRNA leads to decreased expression
of endogenous p63 (Figure 2c).
YAP binds to and stabilizes DNp63a in a c-Abl-
dependent manner. Recently, YAP was shown to bind to
and stabilize TAp73.
25,26 Though YAP has not previously
been demonstrated to bind p63 in vivo, the PPXY motif which
YAP binds to in p73 is conserved in the longer p63 isoforms,
including DNp63a.
20 We ﬁrst co-transfected 293 cells with
mycDNp63a or DNp63a Y449F (PPXY motif point mutant)
and either FLAG-YAP or YAP Y357F (c-Abl phosphosite
mutant) and immunoprecipitated with Flag beads to pull
down YAP. We determined that DNp63a but not the PPXY
motif point mutant binds YAP (Figure 3a lanes 2,3). YAP has
also been shown to be a direct c-Abl substrate
23 and we
further show that the c-Abl phosphosite mutant, YAP Y357F,
does not co-immunoprecipitate DNp63a as well as wild-type
YAP (Figure 3a, lanes 3 and 4).
We next examined the effect of c-Abl phosphorylation on
the YAP–p63 interaction by co-transfecting FLAG DNp63a or
DNp63aYYYFFF (combined c-Abl phosphosite mutant) and
GFP–YAP along with either the inactive c-Abl truncation
mutant (D SH2, SH3 c-Abl) or the hyperactive truncation
mutant (D SH3 c-Abl). Co-immunoprecipitation of p63 and
YAP in these cells revealed greatly diminished binding to YAP
of the DNp63a phosphosite mutant compared with wild-type
DNp63a (Figure 3b, lanes 3 and 5). Furthermore, expression
of hyperactive c-Abl increased binding of YAP to wild-type
DNp63a (Figure 3b, lanes 3 and 4). This effect was reduced
but not completely abrogated for DNp63aYYYFFF (Figure 3b,
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Cell Death and Diseaselanes 5 and 6). These data, along with the YAP phosphosite
mutant result (Figure 3a, lanes 3 and 4) indicate that phosphory-
lation of c-Abl on both YAP and p63 regulate their binding.
Binding of YAP and p63 is also regulated by c-Abl
phosphorylation in the head and neck cancer cells. In a
similar experiment to Figure 2a, we demonstrate that the
binding of endogenous DNp63a and endogenous YAP is
enhanced in c-Abl transfected H357 cells (Figure 3c, left).
Conversely, treatment with the c-Abl selective inhibitior
imatinib
32,33 decreased this interaction (Figure 3c, right).
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Figure1 DNp63aisadirecttargetofthec-Abltyrosinekinase.(a)InvitrokinaseassayemployingrecombinantDNp63aandactive,recombinantc-Ablwascarriedoutas
described in Experimental Procedures. Kinase reactions were fractionated by SDS-PAGE and analyzed by western blot with indicated antibodies (p63a¼p63a
isoform speciﬁc antibody). (b) 293 cells were co-transfected with indicated plasmids or relevant empty vector and Flag-DNp63a immunoprecipitated with Flag antibody.
Immunoprecipitates and representative whole cell lysate (Input) were fractionated by SDS-PAGE and analyzedby western blot with indicatedantibodies. (c) Sequencesfrom
peptides containing phosphorylated tyrosines which overlapped from mass spectrometric analysis of DNp63a of both in vivo and in vitro phosphorylation by c-Abl (see
Supplementary Figure S1) were compared across species: human¼Homo sapien; mouse¼Mus musculus; chicken¼Gallus gallus; frog¼Xenopus laevis;
zebraﬁsh¼Danio rerio. Phosphorylated tyrosine indicated in red. (d) 293 cells were transfected with c-Abl and either empty vector, DNp63a or indicated tyrosine to
phenalanine mutant construct. Whole-cell lysates were fractionated by SDS-PAGE and analyzed by western blot with indicated antibodies (p-p73Y99¼antibody to Tyrosine
99 phosphorylated p73, see text)
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Cell Death and DiseaseSilencing endogenous YAP in the head and neck cancer cells
results in decreased endogenous p63 and prevents further
c-Abl-dependent increase in p63 (Figure 3d). These results
indicate that c-Abl phosphorylation stabilizes DNp63a by
increasing its binding to YAP, similar to the effect of YAP on
TAp73.
23,25,26
Cisplatin stimulates c-Abl phosphorylation of DNp63a
and its binding to YAP. c-Abl is activated by a number
of upstream stimuli, including DNA damage.
27 The
chemotherapeutic agent cisplatin induces c-Abl
phosphorylation of TAp73, as well as YAP, to induce
apoptosis.
13,14,16,23 DNp63 is thought to counter TAp73 in
chemotherapy-induced apoptosis in cancer cells and
DNp63–TAp73 interaction has recently been shown to be
regulated by c-Abl activity in breast cancer.
31,34,35 More
recently, it has been shown that c-Abl can phosphorylate and
regulate the pro-apoptotic TAp63 in mouse oocytes upon
cisplatin treatment.
36 However, direct phosphorylation of
DNp63 by cisplatin-induced c-Abl has not been
demonstrated. We show that cisplatin treatment in H357
head and neck cells leads to an increase in endogenous c-Abl
phosphorylation (Figure 4a), as detected by an antibody
to phosphorylated c-Abl, and a concomitant increase in
DNp63a phosphorylation (Figure 4a), as detected by
the cross-reacting p-p73Y99 antibody (Figure 4a).
Molecular weight comparison with the p63a antibody signal
demonstrates that the cisplatin-induced p-p73Y99 signal is
indeed p63a in these cells (Figure 4a). Cisplatin treament
also induces increased binding of endogenous YAP to
DNp63 (Figure 4b), similar to ectopic expression of c-Abl in
these cells (Figure 3c).
c-Abl phosphorylation of DNp63a regulates viability
in the head and neck cancer cells. To investigate
the effect of DNp63a expression on cisplatin sensitivity
and its regulation by c-Abl phosphorylation, we ectopically
expressed either the empty vector DNp63a or the YYYFFF
phosphosites mutant in H357 cells. DNp63a but not the
c-Abl phosphosites mutant protected the head and neck
cancer cells from loss of viability at all doses of cisplatin
(Figure 4a). Noting that the overexpression of DNp63a
but not the phospho-deﬁcient construct resulted in
increased viability in untreated cells relative to empty
vector, we next examined the effect of endogenous c-Abl
phosphorylation on DNp63a in unstimulated cells.
Endogenous p63 was silenced by siRNA in the head
and neck cells and either empty vector DNp63a or
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Figure 2 DNp63a stability is regulated by c-Abl phosphorylation. (a) H357 head and neck cancer cells were transfected with indicated plasmids and immunoprecipitated
with p63a antibody. Immunoprecipitates were analyzed with indicated antibodies (p63¼pan p63 antibody). (b) H357 cells were transfected with indicated plasmids and
whole-cell lysates were treated were analyzed with indicated antibodies. (c) H357 cells were transfected with indicated siRNA oligonucleotides as described in Experimental
Procedures. Whole-cell lysates were analyzed with indicated antibodies
c-Abl phosphorylation of DNp63a
M Yuan et al
4
Cell Death and Diseasephospho-deﬁcient DNp63a constructs resistant to the siRNA
oligo (Supplementary Figure S2) were transfected. As shown
in Figure 4b, loss of viability ensuing from p63siRNA was
rescued by wild-type DNp63a but not the c-Abl phosphosites
mutant. These results indicate that both DNA damage
stimulated and unstimulated c-Abl activity is important in
regulating DNp63a to maintain viability in the head and neck
cancer cells.
Discussion
In cancer, c-Abl has been implicated as an oncogene in a
number of malignancies with unregulated kinase activity
leading to hyperproliferaton and transformation.
37 In contrast,
c-Abl has also been well-characterized as a DNA damage-
stimulated kinase, activating cell death downstream of
chemotherapeutic agents.
27 For the latter, TAp73 and its
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Cell Death and Diseaseinteracting regulator YAP, have been demonstrated to be key
substrates for c-Abl.
23 Activation of DN isoforms of both p63
and p73 has been shown to counter the pro-apoptotic
signaling of TAp73, as well as p53.
11 YAP has been
demonstrated to be pro-apoptotic in a number of studies, by
binding and activating TAp73, and has recently been
implicated as a tumor suppressor in certain breast
cancers.
21–26,38 Here we show that c-Abl phosphorylates
DNp63a, leading to its increased stability, in part by inducing
binding to YAP, to signal increased proliferation as well as to
counter cisplatin-induced cell death in the head and neck
cancer cells. YAP has also been shown to be pro-growth,
most convincingly in the development of Drosophila
melanogaster, at least, in part, by binding and activating the
TEAD transcription factor.
39,40 It may be that YAP can also
stimulate proliferation in other systems by binding and
stabilizing DNp63a.
Expression of the different p63 and p73 isoforms vary
across different cell types but beyond mRNA levels, post-
translational modiﬁcations such as phosphorylation, as well
asacetylation,sumoylationandubiquitylation,determinetheir
overall expression. The different isoforms themselves may
interact and compete for binding on DNA.
11 Furthermore,
interactingpartners suchasYAPthemselves are regulatedby
similar post-translational modiﬁcations.
22,23 Gonﬂoni et al
36
have recently implicated cisplatin-induced c-Abl phosphoryla-
tion to be stimulate the pro-apoptotic TAp63 isoform in
chemotherapy-induced cell death in oocytes, which comple-
ments our present study showing that c-Abl phosphorylation
of the pro-proliferative DNp63a isoform is protective. These
ﬁndingsclearlyillustratethattofullyunderstandtheroleofp63
and p73 in particular systems, the integration of the activities
of all the isoforms must be assessed. Further work is required
to determine the spatial and temporal kinetics of formation of
the dynamic complexes of p63 and p73 family members and
their regulatory proteins.
Materials and Methods
Cell culture. HEK293 cell line and human breast cancer cell line MCF7 were
obtained from the Cancer Research UK Central Cell Service (Clare Hall, South
Mimms,UK)andwereculturedin10%CO2inDMEMsupplementedwith10%foetal
calf serum (FCS, Sigma, St. Louis, MO, USA). H357, an oral squamous cell
carcinoma head and neck cancer cell line, was kindly given by Dr. Gareth Thomas,
Institute of Cancer, Barts and The London School of Medicine, and was cultured in
KGM medium supplemented with 10% FCS.
Transfections. Cells for immunoprecipitation were seeded at 1.5 10
6 in
10cm dish, at 1 10
5 in a 6-well plate for straight western blot and at 1 10
4 for
96-wellplate,18–24h before transfection. 1mg of each plasmidwas used for 10cm
dish, 200ng of each for 6-well plate and 100ng of each for 96 well plate using
Effectene (Qiagen) for 48h according to manufacturer’s instructions. Plasmids,
cloning and mutagenesis information are described in detail in Supplementary
Materials and Methods. siRNA transfections were carried out in reverse with
Interferin (Polyplus Transfection, Illkirch, France) at 10nM ﬁnal concentration.
siGENOME Non-Targeting siRNA#2 (D001210-02-20) as siRNA control, p63
siGENOME siRNA (D003330-05-0005), c-Abl OnTARGET plus SMARTpool
(L-003100-00-0005) are from Dharmacon (Lafayette, CO, USA). YAP siRNA-
targeting sequence was described previously.
21
Expression of GST–DNp63a. Cultures of E.coli (DH5a) were transformed
withpGEX 6p1-DNp63a plasmidandinducedto expressrecombinant protein using
IPTG(0.5mg/ml) over 4h at 371C. Cells were lysed usingPBSTbuffer andisolated
using glutathione-Sepharose beads.
In vitro kinase assay. A total of 40ml of GST-DNp63a isolated on sepharose
beads was used as substrate and recombinant Abl (New England Biolabs,
Beverly, MA, USA) was used as kinase for in vitro kinase assay and carried out
according to the manufacturer’s instructions. In all, 200U of Abl were used in the
assay.
Immunoprecipitation. Np40 lysis buffer (Sodium chloride 150mM, NP-40
1%, Tris pH 8.0 50mM) was used to extract protein from cell pellet; 1mM DTT,
protease inhibitor cocktail and phosphatase inhibitor (Roche, Basel, CH,
Switzerland) were added into lysis buffer. Protein A Sepharose 4B (Sigma) and
p63a (H129) antibody was use for p63 immunoprecipitation. Flag
immunoprecipitation was carried out using Flag M2 beads (Sigma) following the
manufacturer’s instructions.
Westernblot. ProteinextractswerefractionatedbySDS-PAGEandtransferred
to PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA). Anti- actin, c-Myc
(A14), p63a (H129), pan-p63 (4A4), tubulin, YAP (H-125) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), phospho p73 (Tyr99) antibody, phospho-
c-Abl (Tyr245) (Cell Signalling Technology, Beverly, MA, USA), c-Abl (Ab-3)
antibody (Calbiochem, San Diego, CA, USA) and phosphotyrosine (4G10) antibody
(Upstate, Millipore) were used as manufacture’s recommendation; mouse anti-
human proliferating cell nuclear antigen (PCNA) antibody (Research Monoclonal
AntibodyService, CancerResearchUK, 1:1000).Chemiluminescence detectedby
(AmershamECLPlus,GEHealthcare,ChalfontSt.Giles,UK)or(SuperSignalWest
Pico Substrate, Pierce, Rockford, IL, USA) and the membranes were exposed to
X-ray ﬁlm.
Mass-spectrometry of phosphorylation sites of DNp63a. Re-
combinant GST DNp63a from c-Abl in vitro kinase assays or FLAG–DNp63a
immunoprecipitated from c-Abl co-transfected 293 cells were fractionated by
SDS-PAGE and DNp63a band excised, digested by indicated enzymes and
subjected to mass spectrometric analysis at the Taplin Mass Spectrometry Facility
(Harvard University, Cambridge, MA, USA).
Cell viability. A total of 1 10
4 H357 cells were seeded in 96-well dishes and
transfected and treated as indicated and cell survival determined by MTS assay
according to the manufacturer’s instructions (Promega, Madison, WI, USA).
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. This work was funded by Cancer Research UK and the
Barts and The London Charity.
1. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis
and cancer therapy. Nat Rev Drug Discov 2008; 7: 979–987.
2. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically
expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and
other human cancers. Cell 1997; 90: 809–819.
3. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at
3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-
negative activities. Mol Cell 1998; 2: 305–316.
4. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue
required for limb and epidermal morphogenesis. Nature 1999; 398: 708–713.
5. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for
regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;
398: 714–718.
6. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J et al. p73-deﬁcient
mice have neurological, pheromonal and inﬂammatory defects but lack spontaneous
tumours. Nature 2000; 404: 99–103.
7. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. Chemosensitivity
linked to p73 function. Cancer Cell 2003; 3: 403–410.
8. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z et al. p63 protects the
female germ line during meiotic arrest. Nature 2006; 444: 624–628.
9. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor
predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor
functions for the p53 family. Cancer Cell 2005; 7: 363–373.
c-Abl phosphorylation of DNp63a
MY u a net al
7
Cell Death and Disease10. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. p63 and p73 are
required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:
560–564.
11. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of
isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006;
13: 962–972.
12. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Ruﬁni A, Cheung CC et al. TAp73
knockout shows genomic instability with infertility and tumor suppressor functions.
Genes Dev 2008; 22: 2677–2691.
13. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their
collaboration to induce apoptosis. Nature 1999; 399: 809–813.
14. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M et al. The tyrosine
kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
Nature 1999; 399: 806–809.
15. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational
modiﬁcations in p53 for selectivity in target-gene transcription and tumour suppression?
Cell Death Differ 2007; 14: 1561–1575.
16. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine
kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814–817.
17. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation.
Oncogene 1999; 18: 3923–3929.
18. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA et al.
The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA
2006; 103: 12753–12758.
19. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH et al. The ubiquitin-
protein ligase Itch regulates p73 stability. EMBO J 2005; 24: 836–848.
20. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A et al. Physical interaction
with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276:
15164–15173.
21. BasuS,Totty NF,IrwinMS,SudolM, DownwardJ. Aktphosphorylates theYes-associated
protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.
Mol Cell 2003; 11: 11–23.
22. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G et al. PML, YAP,
and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008;
32: 803–814.
23. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step
in selective activation of pro-apoptotic genes in response to DNA damage. Mol Cell 2008;
29: 350–361.
24. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E etal. The transcriptional
coactivator Yes-associated protein drives p73 gene-target speciﬁcity in response to DNA
Damage. Mol Cell 2005; 18: 447–459.
25. Danovi SA, Rossi M, Gudmundsdottir K, Yuan M, Melino G, Basu S. Yes-associated protein
(YAP)isacritical mediator ofc-Jun-dependentapoptosis.CellDeath Differ 2008; 15:217–219.
26. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by
preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14: 743–751.
27. Shaul Y, Ben-Yehoyada M. Role of c-Abl in the DNA damage stress response. Cell Res
2005; 15: 33–35.
28. Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002; 108: 247–259.
29. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. AIS is an oncogene
ampliﬁed in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97: 5462–5467.
30. Lena AM, Shalom-Feuerstein R, di Val Cervo PR, Aberdam D, Knight RA, Melino G et al.
miR-203 represses ‘stemness’ by repressing DeltaNp63. Cell Death Differ 2008; 15:
1187–1195.
31. Rocco JW, Leong CO, KuperwasserN, DeYoung MP, Ellisen LW. p63 mediates survival in
squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;
9: 45–56.
32. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a
selectiveinhibitoroftheAbltyrosinekinaseonthegrowth ofBcr-Ablpositivecells.NatMed
1996; 2: 561–566.
33. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W et al. Structural
basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003; 112: 859–871.
34. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-
speciﬁc p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
Cancer Res 2006; 66: 9362–9368.
35. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates
chemosensitivity to cisplatin in a biologically deﬁned subset of primary breast cancers.
J Clin Invest 2007; 117: 1370–1380.
36. Gonﬂoni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C et al.
Inhibitionofthec-Abl-TAp63pathwayprotectsmouseoocytesfromchemotherapy-induced
death. Nat Med 2009; 15: 1179–1185.
37. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene
2008; 27: 4385–4391.
38. Yuan M,Tomlinson V, LaraR, Holliday D, Chelala C, Harada T etal. Yes-associated protein
(YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15: 1752–1759.
39. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a
universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120–1133.
40. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction
and growth control. Genes Dev 2008; 22: 1962–1971.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This article is
licensed under a Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0License.Toviewacopyofthislicense,visithttp://
creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)
c-Abl phosphorylation of DNp63a
M Yuan et al
8
Cell Death and Disease